Are vapes harmful? What the evidence says

Vape aerosol contains fewer and lower concentrations of toxicants than cigarette smoke. This is not a contested claim and it follows directly from the absence of combustion. Burning tobacco produces thousands of compounds including tar and carbon monoxide; heating a liquid to aerosol does not.

Nicotine is addictive, and modern nicotine salt formulations deliver it efficiently at high concentration. Dependence forms and is difficult to break, and that is a health effect in its own right regardless of what else the aerosol contains.

Nicotine exposure during adolescence harms brain development in regions governing attention, learning, mood and impulse control, with development continuing into the mid-twenties. This is the strongest and least disputed argument against youth vaping, and it does not depend on any claim about cancer or lung injury.

Aerosol is not water vapor. It carries ultrafine particles that deposit in deep lung tissue, carbonyls including formaldehyde and acetaldehyde produced by thermal decomposition of the solvents, volatile organic compounds, and metals — nickel, chromium, tin, lead — originating in the heating coil and its solder rather than the liquid.

Nicotine has acute cardiovascular effects: it raises heart rate and blood pressure. For people with existing cardiovascular disease this is not trivial.

Liquid nicotine is acutely toxic on ingestion or skin contact, and pediatric exposures are a documented and preventable harm. Devices and refills need to be treated like household chemicals around children and pets.

The strongest positive evidence for e-cigarettes concerns quitting smoking. The Cochrane Collaboration maintains a living systematic review of electronic cigarettes for smoking cessation, and its 2024 and 2025 updates upgraded the key finding to high certainty: nicotine e-cigarettes increase quit rates compared with nicotine replacement therapy such as patches and gum.

The effect size is meaningful but not miraculous — a relative risk of roughly 1.59 against NRT, which in absolute terms is on the order of four additional quitters per hundred. Cochrane also reported no evidence of serious harm in the trials reviewed, while stating plainly that longer and larger studies are needed to evaluate safety properly.

'High certainty' in the GRADE framework Cochrane uses means the reviewers are confident the true effect lies close to the estimate. It is the strongest confidence rating available and it is not awarded casually. This is the single most important thing to know about vaping and it is systematically underreported in US coverage.

Two caveats matter and are often dropped. The trials studied smokers who switched completely, not people who continued smoking while also vaping — and dual use is common in the real world and does not deliver the same benefit. And the products in the trials were generally regulated, refillable or pod-based devices, not 25,000-puff disposables bought unauthorized from a gas station.

No e-cigarette is approved by the FDA as a smoking cessation medication. Approved cessation medicines — nicotine patches, gum, lozenges, inhalers and nasal spray, plus varenicline and bupropion — have been through the drug approval process, which no vape has.

The magnitude of the risk difference. 'Around 95 percent less harmful than smoking' is a widely repeated figure originating in a 2014 UK expert panel exercise. It was an estimate from structured expert judgement, not a measurement, and its authors have been criticized for the methodology. The direction of the comparison is well supported; the specific number is not, and repeating it as a measured fact overstates what is known.

The gateway question. Whether adolescent vaping causes later smoking, or whether the same young people were disposed toward both, is not resolved. Association is consistently observed; causation is contested, and the underlying trend is that youth smoking has fallen to historic lows over the same period that vaping rose.

Population-level effect. Whether e-cigarettes have net reduced or increased tobacco-related harm across the whole population depends on the ratio of smokers who switched to non-smokers who started, and reasonable analysts using the same data reach different answers.

Flavors. Whether flavor availability is primarily a youth-initiation driver or primarily a factor in adult switching is disputed, with credible research supporting both effects. This is the empirical core of the flavor policy fight.

Long-term respiratory and cardiovascular outcomes. Studies find associations between vaping and respiratory symptoms and cardiovascular markers, but disentangling the effect of vaping from prior and concurrent smoking is genuinely difficult, and most people who vape have smoked.

In 2019 a serious outbreak of lung injury among people who vaped produced 2,807 hospitalizations and 68 deaths in the US between March 2019 and February 2020, peaking at more than 200 cases a week in September 2019. The median patient age was 24, two thirds were male, and 15 percent were under 18.

The cause was identified. Vitamin E acetate, used as a thickening diluent in illicit THC vaping cartridges, was found in product samples tested by the FDA and state laboratories and in the lung fluid of patients — and was not found in the lung fluid of people without the condition. THC-containing products from informal sources, obtained from friends, dealers or online sellers, accounted for most cases.

This matters because EVALI is routinely cited as evidence that nicotine vaping causes lung disease. It is not that. It was a contamination event in an unregulated illicit product supply, and cases collapsed once vitamin E acetate was identified and removed from the illicit supply chain.

The correct lesson is narrower and more useful: the danger sat in the unregulated supply, not in the act of vaping as such. That lesson applies directly today to unauthorized products of unverified composition, and to any THC cartridge from an informal source.

There is no long-term outcome data, and there cannot be yet. Widespread e-cigarette use in the US began around 2015. The disease outcomes that define smoking's harm — lung cancer, COPD, cardiovascular disease — develop over decades. Any confident claim about the thirty-year consequences of vaping is an extrapolation, whichever direction it points.

Flavor chemical inhalation toxicology is largely unstudied at the scale of the market. Hundreds of flavor compounds are in use; a small number have been examined for inhalation safety. Food safety approval concerns eating, and tells you nothing about what happens when a compound is heated and drawn into the lungs.

The high-capacity disposables that now dominate the market are barely studied at all. Almost all published research used earlier device generations at lower nicotine concentrations. A 25,000-puff device at 5 percent nicotine salt is not the product most of the evidence base was built on.

Because unauthorized products have not been reviewed by any regulator, their actual composition is unknown even in principle. Studies of them are studies of whatever happened to be in the units tested.